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IFN-y mediates stimulation of complement C4 biosynthesis in
human proximal tubular epithelial cells
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IFN.y mediates stimulation of complement C4 biosynthesis in human
proximal epithelial cells. The liver has been presumed to be the main source
of complement deposited in inflammatory lesions such as in glomerulone-
phritis. In a previous study, however, it was demonstrated that renal
tubular cells synthesize C3 in vitro. Furthermore, it was shown by others
that C4 gene transcripts were detectable in situ in renal tubular cells.
Therefore studies were initiated to investigate the synthesis of C4 by
proximal tubular epithelial cells (PTEC) in vitro. Biosynthetic labeling
experiments showed de novo synthesis of C4 by PTEC. The synthesis of
C4 by PTEC and its regulation by IFN-y was fully inhibitable by the
addition of cycloheximide, indicating that protein synthesis is required for
an increase in C4 secretion. Addition of increasing concentrations of
IFN-y enhanced the production of C4 by PTEC in a dose dependent
fashion, with a 2.5-fold maximum. Kinetic experiments demonstrated
higher levels of C4 production when stimulated with IEN-y for up to 72
hours. The hemolytic activity of C4 present in culture supernatants of
PTEC decreased during the culture period as assessed by hemolytic
titration. Northern blot analysis showed no enhancement of C4 mRNA in
LFN-y treated PTEC, indicating that IFN-y regulates C4 production at a
post-transcriptional level. Antibody blocking experiments confirmed that
regulation of C4 production was directly mediated by IFN-y. From this
study it was concluded that renal cells are able to synthesize complement
components that could possibly play a role in inflammatory responses
evolving in the kidney.
The complement system is of vital importance for the normal
host defense. Activation of this system occurs via a cascade
system, resulting in several biological responses, including
generation of inflammatory mediators [1]. The resulting inflam-
mation can play a role in the pathogenesis of disease. In the
kidneys of patients with membranoproliferative glomerulone-
phritis (MPGN) and lupus nephritis deposition of complement
products is mostly demonstrated in association with immune
complex-mediated lesions [2].
Most human complement components are synthesized in the
liver and circulate as plasma proteins [3, 4]. Thus, the liver has
been presumed to be the main source of complement production
and indirectly responsible for deposition in inflammatory lesions.
Several studies, however, have also shown production of comple-
ment in the kidney. For instance in lupus nephritis prone mice
such as the MRL lpr/lpr mouse, marked differences in expression
of complement mRNA at local sites of inflammation are found,
which suggests that local production of complement may play a
role in the pathogenesis of chronic glomerulonephritis [5]. In
normal human kidneys mRNA transcripts for C4 and factor B
have also been demonstrated [6]. From these studies it remained
unclear which cell types in the kidney are the source of locally
produced complement. It has been presumed that infiltrating
macrophages are responsible for the observed complement prod-
ucts. Proximal tubular epithelial cells (PTEC) may be responsible
for complement production, since we showed in a previous study
that cultured PTEC synthesize the third component of comple-
ment (C3) in vitro [7]. Furthermore, in a recent study by Witte and
collegues the expression of the fourth component of complement
(C4) in normal and diseased kidneys was determined by in situ
hybridization, showing localization of C4 gene expression in
tubular epithelial cells [8]. In the present study we demonstrate the
biosynthesis of C4 by PTEC and the effect of interferon-gamma on
C4 production.
Methods
Reagents
BSA, collagenase, cycloheximide, o-phenylene-diamine,
trypsin, epidermal growth factor (EGF), hydrocortisone, insu-
lin-transferin-selenate, triiodothyronine (Sigma Chemical Co.
St. Louis, Missouri, USA), Dulbecco's modified Eagle's me-
dium (DMEM), Ham's Fl2 medium, M199 methionine-free
medium, (Seromed, Biochrom. K.G., Berlin, Germany), biotin,
streptavidin peroxidase conjugate (Zymed Laboratories Inc.,
San Francisco, California, USA), rIFN-y (Bioferon, Lautheim,
Germany), vitrogen bovine dermal collagen type 1 (Collagen
Corporation, Palo Alto, California, USA), fetal calf serum, new
born calf serum (HyClone Laboratories Inc., Logan, Utah,
USA) were purchased as indicated. Half isotonic VBS contain-
ing 0.05% gelatin, 0.15 mM CaC12 and 0.5 ma'i MgC12 and 3%
dextrose (DGVB ) was used as diluent in hemolytic assays.
Monoclonal mouse anti-human C4 antibodies were provided by
Dr. L.E. Hack (Central Laboratory for Blood Transfusion,
Amsterdam, The Netherlands).
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Proximal tubular epithelial cell cultures
PTEC were cultured following the protocol as described by
Detrisac et al [9] in serum-free Dulbecco's modified Eagle's
medium/Ham's F12 medium 1:1, supplemented with insulin (5
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Fig. 1. Morphological appearance and dome
formation of cultured proximal tubular
epithelial cells (PTEC), Cultured PTEC show
the characteristic morphology described by
Detrisac et a! [9]. (original magnification x
200)
gIml), selenium (5 ng/ml), transferrin (5 g/ml), tri-iodothyro- cultured using multi-well tissue culture plates (Costar, Cam-
nine (4 pg/ml), epidermal growth factor EGF (10 ng!ml) and
hydrocortisone (36 ng/ml) on a matrix of bovine dermal collagen
type 1 matrix and FCS proteins. Explant cultures were obtained
from kidneys not suitable for transplantation because of tech-
nical reasons or from healthy tissue of nephrectomy specimens
obtained after operation. The PTEC population obtained after
culturing was characterized by its morphologic appearance and
by the formation of "domes" (Fig. 1). Immunofluorescence
phenotyping with various monoclonal antibodies (MAbs) was
done as described [10]. The MAbs used were anticytokeratin
(RGE 53, Eurodiagnostics, Apeldoorn, The Netherlands), anti-
epithelial membrane antigen (EMA, Dako, Glostrup, Den-
mark), and two MAbs directed against the adenosine-deami-
nase binding protein (ADBP), designated 1071, and 1072 [7, 10].
PTEC monolayers obtained between passages 2 and 6 were
bridge, Massachusetts, USA). The cells were rinsed and cul-
tured for different time intervals in medium alone or in medium
containing various concentrations of recombinant IFN-y. At
the end of the experiments culture supernatants were collected,
centrifuged, and stored at —20°C. PTEC were trypsinized to
determine the number of cells, using a Coulter counter (Coulter
Electronics Ltd., Luton, England, UK). The viability and
number of the IFN-y treated PTEC during the experimental
period did not differ from control cells.
Sandwich ELISA for quantification of C4
For quantification of C4 production the wells in microtiter
plates (Titertek Flow Laboratories, Zwanenburg, The Nether-
lands) were coated with affinity-purified goat IgG anti-human
C4 for two hours at 37°C. After washing, PTEC supernatants
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were incubated in the wells for one hour at 37°C. The plates
were treated with monoclonal biotin-labeled mouse anti-human
C4, peroxidase labeled streptavidin and o-phenylene-diamine.
Between the incubation steps the plates were washed thor-
oughly with PBS/0.05% Tween 20. The reaction was stopped
using 1 M H2S04 and the amount of reacted substrate was
determined using a Titertek Multiskan (Titertek Flow Labora-
tories) at 0D492. The concentration of C4 was calculated from
a standard curve constructed by using dilutions of NHS with
known concentrations of C4.
Biosynthetic labeling, and im,nunoprecipitation
Biosynthetic labeling experiments were performed by incu-
bating PTEC monolayers in methionine-free DMEM containing
[35S]methionine (500 CiIml) for two hours. At the end of the
pulse period, extracellular media were harvested and monolay-
ers were rinsed and lysed in buffer, containing 20 mM Tris, 10
mM EDTA, 100 ms NaC1, 0.5% NP-40, antipain (1 pg/ml),
pepstatin A (1 sg/ml), chymostatin (1 p,glml) and leupeptin (1
j.gIml). Before immunoprecipitation, media and cell lysates
were preabsorbed for four times at 4°C with 100 d of 10%
(vol/vol) formalin-fixed Staphylococcus aureus and then S s1 of
mouse MAb directed against human C4 was added to the
samples. An isotype-matched control MAb was included in the
experiment. After incubation for 16 hours at 4°C, antibody-
antigen complexes were recovered by using 100 pi of 10%
Staphylococcus aureus. The immunoprecipitates were centri-
fuged, washed, and subjected to SDS-PAGE (7%) under reduc-
ing conditions. The gels were fixed, impregnated with Amplify
(Amersham Corp., Arlington Heights, Illinois, USA), dried and
exposed at —70°C to Kodak XAR-5 ifims (Eastman Kodak,
Rochester, New York, USA).
Inhibition of C4 synthesis by cycloheximide
Replicate PTEC monolayers were grown in multiwell tissue
culture plates. The cells were washed and the medium replaced
with or without IFN-y. Each set was further incubated with or
without 1 jsg/ml cycloheximide (CHX), and supernatants were
obtained at 24, 48, 72 hours and assessed for C4. Thereafter all
cells were rinsed, washed and replaced with medium and
cultured for an additional 24 hours. The supernatants were
harvested and assessed for C4. At the same time cells were
harvested by trypsinization to determine the number of cells.
Hemolytic assay for C4
The activity of C4 present in culture medium was determined
in a hemolytic assay. Sheep erythrocytes (Es) sensitized with
rabbit of C4 deficient serum were incubated with culture media
(0.1 ml) obtained after 24, 48 and 72 hours of incubation, The
reaction mixture was incubated for one hour at 37°C in a
shaking water bath. The hemoglobin release was measured
spectrophotometrically after adding 1.5 ml PBS and centrifuga-
tion. The number of effective molecules was expressed as Z
values as described by Borsos, Rap and Mayer [11]. Dilutions
were made in DGVB.
RNA extraction and Northern blot analysis
RNA was extracted from monolayers of PTEC cultured in
T75 flasks. Total RNA extraction was performed as described
by Chomczynski and Sacchi [121 using RNA-zol (CINNA!
Table 1. Stimulation of C4 production by IFN-y in different PTEC
cell lines
C4 ng/106 cells/24 hr
Cell line number 1 2 3 4
Medium 2.2 1 5.3 1 8.2 2 18.0 3
Medium + IFN-y 7.8 2 10.6 4 20.3 1 54.4 5
Degree of stimulation 3.5 2 2.5 3
PTEC were cultured in the presence or absence of IFN-y. These data
are the mean SD of duplicate measurements of triplicate cultures.
Biotec Lab, Int, Inc.). An amount of 20 g of total RNA was
separated on a agarose gel containing formaldehyde and blotted
on nitrocellulose filters (Gene-Screen Plus, Du Pont, Wilming-
ton, Delaware, USA). Standard procedures were used for
electrophoresis, RNA transfer and hybridization [13]. The 5'
cDNA probe Pa, a 476 bp BamH l/Knp 1 restriction fragment
from the full-length C4 cDNA clone, pAT-A, was used in these
experiments [14].
Results
In a previous study we could demonstrate the synthesis of C3
by PTEC [7]. Therefore PTEC were also analyzed for synthesis
and secretion of other complement components, including C4.
Eight PTEC cultures of different kidney origin which had grown
confluent were incubated with culture medium for 48 hours.
Supernatants were harvested and assessed for C4 production by
ELISA. All PTEC were in the same culture passage. The
results show a great difference in baseline production of C4 by
PTEC of different kidney origin with a minimum of 2.2 ng/106
cells/24 hr to a maximum of 18 ng/106 cells/24 hr and a mean
production of 8.7 ngIlO6 cells/24 hr. In Table 1 the results are
shown of four of the eight different cell lines cultured in the
presence or absence of IFN-y (400 sIml). The cell lines are
numbered from 1 to 4. In the following results the number of the
cell line used in the experiment will be mentioned in the figure
or table. Kinetic experiments with the same four different
PTEC cell lines, incubated for 96 hours and assessed for C4 at
timed intervals, showed a time dependent increase of C4
production by all cell lines cultured (Table 2). To determine
whether this C4 is synthesized de novo, confluent monolayers
of PTEC were metabolically labeled with L-[35S] methionine for
two hours. The cells were then lysed and C4 was immunopre-
cipitated from the supernatants and cell lysates, and analyzed
by SDS-PAGE under reducing conditions, and autoradiogra-
phy. As shown in Figure 2 intracellular (I) C4 was synthesized
as a single chain precursor of —200 kD (pro-C4), that is secreted
extracellular (E) as native C4 composed of three disulphide-
linked polypeptide chains a, f3, and y with Mr of 93 kDa, 78 kDa
and 30 kDa, respectively. The a-chain is probably partly
degraded by proteolysis, because the abundance of the a band
is much less compared with the two other bands. The results
indicate that C4 produced by PTEC is similar in size to C4
present in fresh human plasma. Immunoprecipitation with a
irrelevant MoAb as a specificity control showed no specific
bands (C). Confluent PTEC monolayers stimulated with IFN-y
(400 /.LJml) or in medium alone were cultured further in medium
alone or in medium containing 1.0 p.g/ml cycloheximide. At
timed intervals supematants were harvested and assessed for
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Table 2. Kinetics of production of C4 in different PTEC cell lines
Table 3. Reversible blocking by cycloheximide of C4 production by
PTEC in the presence and absence of IFN-y
Supernatant
obtained after
C4 ng
IFN-y — — + +
CHX — + — +
24 hours 5.5
(0.2)
2.0
(0.4)
10.1
(1.0)
2.4
(0.3)
48 hours 13.0
(1.2)
2.5
(0.5)
37.4
(2.2)
2.2
(0.5)
72 hours 17.0
(2.0)
2.1
(0.2)
79.0
(2.0)
2.8
(0.4)
+24 hours 5.4
(0.6)
5.2
(0.4)
9.8
(1.1)
10.1
(1.4)
C4 production by PTEC (cell line 2) in the presence and absence of
IFN-y was assessed at timed intervals, with or without cycloheximide.
After 72 hours the cells were washed, resuspended in culture medium
and incubated for another 24 hours at 37°C and also assessed for C4 in
the supernatants. The results are the mean of four determinations I
SD. The SD values are between brackets.
Fig. 2. Biosynthetic labeling experiments for C4 synthesis in PTEC.
Monolayers of PTEC were incubated at 37°C in the presence of 135S]
methionine (500 jsCi/ml) for 2 hours. Cell lysates (I) and supernatants
(E) were immunoprecipitated with a monoclonal antibody against
human C4. A non-specific MoAb was used as a negative control (C).
Immunoprecipitates were analyzed on 7% SDS-PAGE gel under reduc-
ing conditions and fluoroautoradiography. Numbers on the left are in
kD.
C4 production by ELISA. Monolayers that were kept for 72
hours with CHX were washed and incubated for another 24
hours in fresh medium and subsequently assessed for C4
secretion. Stimulated PTEC cultured in presence of CHX
produced 2.4 ng/106 cells and unstimulated 2.0 ngIlO6 cells after
culturing for 24 hours. In the absence of CHX the production of
C4 was 10.1 ng and 5.5 ng, respectively. After incubation for
another 24 hours in fresh medium the production of C4 was for
both stimulated and unstimulated cells comparable to the pro-
duction of C4 by PTEC not being blocked with CHX (Table 3).
Hemolytic activity of C4 produced by PTEC was determined
in a hemolytic titration assay. Supernatants of various PTEC
cultures obtained after 24, 48 and 72 hours of incubation in
culture medium were collected and assessed for the amount of
C4 by ELISA, and subsequently diluted in DGVB and
titrated in a hemolytic assay using C4 deficient serum. The
activity of C4 present in pooled NHS was 2.4-fold higher than
the hemolytic activity of C4 present in PTEC supernatants,
compared on a weight basis (data not shown). Table 4 shows a
time-dependent linear increase of the amount of C4 and the
number of effective C4 molecules produced by PTEC. How-
ever, the ratio between the amount of C4 and the hemolytic
activities declined. This might be caused by degradation of C4
in culture supernatants.
Enhancement of complement production by IFN-y has been
reported for several different cell types, including monocytes,
fibroblasts and endothelial cells [15—19]. To investigate whether
C4 production by PTEC could be enhanced by IFN-y, confluent
PTEC monolayers were incubated in media containing increas-
ing concentrations of IFN-y for 72 hours. Supernatants were
Time in culture
24 hours
48 hours
72 hours
96 hours
Cell line
number
Without IFN-y With IFN-y
1 2 3 4 1 2
-
3 4
2.2 5.3 8.2 18.0 7.8 10.6 20.3 54.4
(1) (1) (2) (3) (2) (2) (3) (3)
7.1 13.0 15.6 27.2 29.2 37.4 42.5 86.7
(2) (3) (3) (4) (4) (3) (2) (5)
11.0 17.2 19.3 35.1 60.1 79.1 85.2 109.2
(1) (3) (3) (5) (5) (4) (1) (7)
16.4 23.4 26.1 41.5 68.3 85.2 89.2 115.8
(4) (3) (4) (3) (5) (7) (3) (8)
C4 production in different PTEC cell lines, incubated for up to four days in the absence and presence IFN-y (400 U/mI), was assessed at timed
intervals. The results are the mean of six determinations 1 SD. The sn values are between brackets.
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Time of culture
hr C4 ng
Hemolytic
activity (Z) Ration
24 7.0 0.24 1.00
48 11.6 0.34 0.86
72 17.3 0.41 0.69
a The ratios of hemolytically-active C'+ as compared with total C4
protein for each time point. The functional activity of C4 produced by
PTEC compared with a dilution of NHS containing the same concen-
tration of C4 already after 24 hours showed a difference of 42%. The
results in Table 3 from one out of two experiments are from a single
experiment with cell line 3.
30
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Fig. 3. Effect of increasing concentrations of IFN--y on the production
of C4 by FTEC in culture. Confluent cells were cultured for 72 hours
and subsequently culture supernatants were collected and assessed for
C4 protein by ELISA. The data are expressed as the mean su of
duplicate measurements of triplicate cultures. (Cell line # 3)
harvested and assessed for C4 production by ELISA. Stimula-
tion of PTEC with IFN-y (25 to 800 /ml) enhanced the baseline
production of C4 (8 ng/106 cells/24 hr) dose dependently to a
maximum of 20 ng/106 cells/24 hours (Fig. 3). The enhancement
of C4 production was most pronounced when the concentration
of IFN-y increased from 100 /ml to 200 jdml. Concentrations
IFN-y higher than 400 p/mI show no additional rise in C4
production.
To investigate the kinetics of C4 production after IFN-y
stimulation, PTEC monolayers were cultured for four days in
the presence of 400 pJml IFN-y or in medium alone. Culture
supernatants were collected at timed intervals and assessed for
C4 by ELISA. As shown in Figure 4 the production of C4
increases linearly in time for unstimulated cells to a maximum
of 23 4 ngIlO6 cells. In the presence of IFN-y there is a
profound increase of C4 production from 24 hours to 72 hours of
stimulation.
To determine whether IFN-y mediates C4 synthesis at a pre-
or post-transcriptional level, analysis of C4 mRNA transcripts
was performed by Northern blotting. PTEC monolayers were
incubated for various time periods with IFN-y or medium
alone. Then total RNA was isolated from each culture and 20 pg
of RNA were electrophoresed, blotted onto nitrocellulose and
Time, hours
Fig. 4. Kinetics of C4 production by PTEC in the absence and pres-
ence of IFN-y. Replicate PTEC monolayers were incubated for 4 days
in the presence of IFN-y (400 UIml) (0) or in medium alone (•). At
timed intervals culture supernatants and cells were collected and
analyzed for C4 protein and the number of cells. Values are the mean
SD for duplicate determinations of triplicate cultures. (Cell line # 2)
C4 mRNA transcripts were detected by hybridization using a
specific cDNA probe. As a control, the amount of p-actin
mRNA in IFN-y treated or untreated cells was also determined.
The Northern blot analysis (Fig. 5) demonstrated the presence
of a full length 5.5 kb species of C4 mRNA in all cultures. There
was no increase of C4 mRNA after stimulation with IFN-y,
suggesting that IFN-y mediates C4 production at a post-tran-
scriptional level. To confirm that the regulation of C4 produc-
tion by PTEC is a specific property of IFN-y, antibody blocking
experiments were performed. Therefore F(ab')2 fragments of
rabbit IgG anti-human IFN-y and normal rabbit IgG were used
to prevent any possible Fc interaction on PTEC. Replicate
PTEC monolayers were cultured in the presence of IFN-y
and/or the various antibodies. The results in Figure 6 demon-
strate a 3.5-fold increase in C4 production after IFN-y treat-
ment as compared to medium alone. Addition of F(ab')2 frag-
ments of rabbit IgG anti-human IFN-y to the IFN-y stimulated
cultures completely neutralized the regulating effect of IFN-y,
whereas F(ab')2 fragments of normal rabbit IgG had no effect.
One way analysis of variance showed that there was no
significant difference between all controls and the IFN-y neu-
tralized culture and that the difference between controls and
IFN-y stimulated cultures was significant (P < 0.01).
Discussion
The complement system plays an important role in the
humoral immune response. Several studies have shown that
hepatocytes in the liver are the main site for systemic comple-
ment synthesis. However, many of the complement compo-
nents are also synthesized by other cell types at extrahepatic
sites, such as mononuclear phagocytes [20], fibroblasts [211 and
epithelial cells of the lung [221 and intestine [23]. In the case of
several renal diseases, complement deposits associated with
immune complexes are found in the kidney. However, it has
been demonstrated that complement components can be found
without deposition of immunoglobulins [241, suggesting a pos-
sible local production of complement in the kidney. Indeed, it
Table 4. Hemolytic activity and amount of C4 in PTEC supernatants
obtianed at different time points
ci)
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has been demonstrated that C4 mRNA is expressed in normal
human kidney [6]. Previously Passwell et al [5] observed a
higher expression of C2, C3, C4 and factor B mRNA in the
kidneys of an SLE-sensitive mouse strain compared to normal
mice. The increased mRNA expression correlated with inter-
stitial and glomerular macrophage infiltrates. But in these
studies, it still remained unclear which cell type was responsible
for the local complement production. More recently Witte et a!
have shown by in situ hybridization techniques that C4 tran-
scripts are present in renal tubular epithelial cells [8]. However,
C4 expression did not differ between diseased and normal
kidneys, suggesting that local expression of the C4 gene did not
contribute to the development of glomerulonephritis. This
study shows that human PTEC synthesize and secrete comple-
Fig. 5. Northern blot analysis of the effect of
IFN-y on the expression of C4 mRNA by
PTEC in culture. Cells were incubated in the
presence of 400 U/mi IFN-y (+) or in medium
alone (—). After 24 and 48 hours of IFN-y
treatment total RNA was isolated, and
from each culture 20 g RNA were
electrophorësed, blotted and hybridized. The
upper row shows hybridization to a human C4
cDNA probe, whereas the lower row shows
hybridization to a /3-actin probe. (cell line #
4)
Fig. 6. Effect of rabbit anti-human IFN-y on
IFN-y-mediated C4 production by PTEC.
PTEC were incubated with IEN-y (400 U/mI),
IFN-y together with F(ab')2 fragments of
rabbit IgG anti-IFN-y (1:250), F(ab')2 anti
IFN-y or F(ab')2 fragments of normal rabbit
IgG. After 72 hours culture supernatants were
harvested and analyzed for C4 and were
expressed as production of C4 per 24 hours
by 106 cells. Values represent the mean SD
of duplicate determinations of quadruplicate
cultures. (Cell line # 1)
ment C4 in vitro, and that C4 synthesis is regulated by IFN-y.
Reasons for the variation in baseline production of C4 by
different PTEC cultures are not clear at present. The baseline
production of C4 by cell lines established from different pieces
of kidney of the same donor was comparable, suggesting a
donor dependency of C4 production. No relationship with
clinical conditions of the kidney donor was found. However, it
was observed that the production of C4 decreased gradually
after repeated passages; therefore, experiments were done
using PTEC between passage 2 and 6. C4 production was
already clearly detectable in primary cultures (data not shown),
indicating that C4 production by PTEC is not a result of
dedifferentiation in vitro. The size and subunit structure of C4
produced in PTEC were similar to that observed in both
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Hep-G2 cells [25] and in human monocytes [26, 27]. Experi-
ments using cycloheximide showed that protein synthesis was
required for an increase in C4 secretion after IFN-y stimulation.
The functional activity of PTEC-C4 was decreased compared
with plasma C4, indicating that there is probably a partial
inactivation of the C4 molecule during culturing. Addition of
IFN-y to the cultures increased synthesis of C4 in a dose
dependent fashion, with a maximal 2.5-fold increase above
baseline. The effect of IFN-y was also studied at the mRNA
level, using Northern blot analysis, demonstrating that the
increase in the rate of C4 protein synthesis after IFN-y treat-
ment was not reflected at the C4 mRNA levels. This suggests
that IFN-y probably regulated C4 synthesis at a post-transcrip-
tional level. Therefore, although no difference has been found in
C4 mRNA expression between diseased and normal kidneys
[8], the local production of C4 might be increased in inflamma-
tory kidney diseases. In human monocytes it has been shown
by Lappin and Whaley that IFN-y induced post-transcriptional
modulation of complement synthesis [28]. Blocking studies with
neutralizing antibodies to IFN-y, demonstrated that the effects
mediated by IFN-y on C4 production were specific for this
cytokine. The great difference in baseline production of C4 by
PTEC of different kidney origin could be of importance in the
pathogenesis of various kidney diseases. Complement protects
against immune complex deposition in the kidney by maintain-
ing the complexes in solution. Low levels of complement
components (C) may cause immune complex deposition in the
kidney and circulating immune complexes as seen in mesangial
lupus nephritis. On the other hand, high levels of C may cause
deposition of complement on the cell membranes. Not only
systemic concentrations of C determine the complement levels,
but also the local production rate of C might influence these
levels and therefore could be of importance in protection
against immune complex deposition. These results and findings
of a previous study that demonstrated C3 production by PTEC
[7] could also be of pathogenic significance in nonimmune
chronic renal diseases of the tubulointerstitium. In addition
studies by Hosttetter et al showed that elevations in ammonia
concentrations per nephron promotes tubular injury that is
triggered by the interaction of ammonia with C3. Amidated C3
leads to the promotion of interstitial inflammation by several
mechanisms, including the formation of the membrane attack
complex [29].
When more kidney tissue of different kidney origin is avail-
able, it would be interesting to investigate the relation between
production rate and renal pathology. Also, the production of
complement components by PTEC other than C3 and C4
require further attention.
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